Proposed private placement of up to 26,000,000 new ordinary shares in Supergenics, representing approximately 27.96% of the existing total number of issued shares of the Company at an issue price to be determined and announced later ("Proposed Private Placement")

Proposed diversification of the principal activities of Supergenics Group to include the provision of administrative health care services, operating of medical laboratories and development of regenerative treatment products for medical treatment and wellness ("Proposed Diversification")